<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724409</url>
  </required_header>
  <id_info>
    <org_study_id>201805910</org_study_id>
    <secondary_id>P50CA174521</secondary_id>
    <nct_id>NCT03724409</nct_id>
  </id_info>
  <brief_title>Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases</brief_title>
  <official_title>Selective Intra-arterial Injection of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumor Patients With Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandeep Laroia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it&#xD;
      is administered intravenously for patients with neuroendocrine tumors that have spread to the&#xD;
      liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [90]Yttrium-DOTATOC is a radioactive drug used for peptide receptor radionuclide therapy&#xD;
      (PRRT). In other studies, 90Y-DOTATOC has been administered through a vein (IV) to target&#xD;
      somatostatin receptor positive tumor tissue. The DOTATOC identifies the tumor through the&#xD;
      somatostatin receptor and links to it, attaching the radioactive molecule 90Yttrium to the&#xD;
      malignant cell.&#xD;
&#xD;
      This study expands the initial work to examine if administering the drug 90Y-DOTATOC directly&#xD;
      to the liver is safe for patients with neuroendocrine tumors whose disease has spread to&#xD;
      their tumor. We don't know how of the 90Y-DOTATOC is safe to administer. We want to learn&#xD;
      what the maximum safe dose is and what the side effects are related to that dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a sequential early phase 1 study using Storer's phase 1 design B.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate liver toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for liver enzymes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in platelet counts</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate bone marrow toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in absolute neutrophil count</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate bone marrow toxicity using using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for absolute neutrophil count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90Y-DOTATOC distribution</measure>
    <time_frame>48h post-infusion</time_frame>
    <description>Determine the distribution of 90Y-DOTATOC using post-treatment imaging</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[90]Y-DOTATOC</intervention_name>
    <description>Intra-arterial infusion to the liver of [90]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>90Y-DOTATOC</other_name>
    <other_name>90Y-DOTA-Phe1-tyr3-Octreotide</other_name>
    <other_name>[90]Yttrium-DOTATOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and the willingness to provide informed consent&#xD;
&#xD;
          -  Pathologically well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2).&#xD;
&#xD;
          -  Primary tumor location should be known or believed to be midgut.&#xD;
&#xD;
          -  At least one tumor in the liver that is positive with [68]Ga-DOTATATE (NETSPOT).&#xD;
             Imaging must be performed within the past 6 months.&#xD;
&#xD;
          -  Liver lesions not amendable to other therapies (surgery, ablation) and have progressed&#xD;
             after treatment with octreotide/lanreotide and/or other treatments. (everolimus,&#xD;
             sunitinib).&#xD;
&#xD;
          -  Karnofsky performance status of at least 70&#xD;
&#xD;
          -  Absolute neutrophil count of at least 1,000 cells/mm3&#xD;
&#xD;
          -  Platelet count of at least 90,000 cells / mm3&#xD;
&#xD;
          -  Total bilirubin ≤ 2 x the upper limit of normal when adjusted for age&#xD;
&#xD;
          -  AST and ALT ≤ 5 x the upper limit of normal when adjusted for age&#xD;
&#xD;
          -  Serum creatinine ≤ 1.2 mg/dl; if serum creatinine is &gt;1.2 mg/dl nuclear GFR will used&#xD;
             for potentially eligible participants.&#xD;
&#xD;
          -  Agrees to contraception.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Liver tumor involvement greater than 70% by cross sectional imaging&#xD;
&#xD;
          -  Extra-hepatic visceral and osseous metastases&#xD;
&#xD;
          -  Concomitant therapy for tumor (except for somatostatin analogs or bisphosphonates)&#xD;
&#xD;
          -  Previous PRRT or other liver directed therapy within 12 months of consent&#xD;
&#xD;
          -  Women who are pregnant, breast feeding or breast pumping.&#xD;
&#xD;
          -  Another concurrent malignancy on active therapy&#xD;
&#xD;
          -  Previous external-beam radiation therapy to a kidney (including scatter dose)&#xD;
&#xD;
          -  Therapeutic investigational drug within 4 weeks of therapy.&#xD;
&#xD;
          -  Subjects for whom, in the opinion of their physician, a 24-hour discontinuation of&#xD;
             somatostatin analogue therapy represents a health risk.&#xD;
&#xD;
          -  Sandostatin LAR injection within 4 weeks or lanreotide injection within 8 weeks of&#xD;
             proposed therapy.&#xD;
&#xD;
          -  Inability to lie down supine for study procedure.&#xD;
&#xD;
          -  Reaction to IV contrast used for the angiogram.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring hospitalization, symptomatic congestive heart failure, unstable&#xD;
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. S O'Dorisio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Laroia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015 Jan;17(1):29-37. doi: 10.1111/hpb.12326. Epub 2014 Sep 4. Review.</citation>
    <PMID>25186181</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sandeep Laroia</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PRRT</keyword>
  <keyword>Radionuclide</keyword>
  <keyword>DOTATOC</keyword>
  <keyword>intra-arterial</keyword>
  <keyword>peptide receptor radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared as per approved IRB application and the subject's opt-in preferences. Data will not be provided from subjects who decline data sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Considered upon request.</ipd_time_frame>
    <ipd_access_criteria>Contact study PI regarding data sharing. A non-disclosure agreement may be required between institutions dependent upon the data requested.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

